Aptose Biosciences Inc remains stable amid significant corporate developments.
This week, Aptose Biosciences Inc (APS.TO) has shown no change in its stock price, closing at C$2.40. The company has been in the spotlight recently due to its acquisition by Hanmi Pharmaceutical and ongoing clinical trials, which continue to shape its market narrative.
Investor takeaway: With a stable stock price and recent developments in clinical trials and acquisitions, investors should monitor Aptose's progress closely, especially as it navigates the complexities of its new corporate structure.
Advertisement
Aptose Biosciences Inc
APS.TO
APS.TO
Aptose Biosciences Inc
WealthAwesomeMarket cap
$6.13M
52W high
$2.59
52W low
$1.41
1W change
+0.00%
Beta
0.34
Analyst Price Targets
Based on analyst covering APS
Wall Street analysts forecast APS stock price to fall 1.7% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.36
-1.7% Upside
Current Price
C$2.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APS's historical volatility
30-Day Vol
52.7%
Annualized
90-Day Vol
48.9%
Annualized
Trend (90d)
-0.0%
Annualized drift
90d Mean
C$2.40
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.40 | C$2.00 โ C$2.88 |
| 60 trading days | C$2.40 | C$1.86 โ C$3.10 |
| 90 trading days | C$2.40 | C$1.75 โ C$3.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Aptose's Stock Holds Steady at C$2.40
The stock's stability reflects investor sentiment amidst ongoing corporate developments and clinical trial progress.
Bull case
The successful completion of the acquisition by Hanmi Pharmaceutical could give Aptose more resources and expertise. This support may enhance its drug development pipeline and strengthen its position in the market.
Bear case
Despite the acquisition, Aptose's financial situation raises concerns. The company has a negative return on equity and no profit margin, which could deter risk-averse investors.
Current Price Action
Advertisement
Aptose Biosciences Inc closed at C$2.40 this week, reflecting a 0.00% change over the last day and week. Year-to-date, the stock has gained 18.81%, indicating some resilience in a challenging market environment.
Recent Corporate Developments
Aptose has been in the headlines recently due to its acquisition by Hanmi Pharmaceutical, which was completed on June 30, 2026. This acquisition is seen as a significant step in the company's strategic development. Additionally, Aptose presented clinical data from its TUSCANY Phase 1/2 trial at the EHA Congress, highlighting safety and efficacy data for its tuspetinib triplet therapy in treating newly diagnosed acute myeloid leukemia (AML).
Technical Picture
From a technical standpoint, Aptose is trading above its 50-day moving average of C$2.25, representing a 6.4% increase, and its 200-day moving average of C$2.14, showing a 12.3% gain. The stock has a 52-week range of C$1.41 to C$2.59, currently sitting at 84% of this range. The beta of 0.34 indicates lower volatility compared to the broader market, while the latest trading volume of 2,945 shares is slightly below the 20-day average volume of 3,425 shares.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
